Articles tagged with Multiple Sclerosis
Researchers found that significantly reducing dietary methionine slows the progression of inflammatory and autoimmune disorders like multiple sclerosis. Methionine fuels T cells, which can cause inflammation and damage if it lingers.
Scientists have made an important discovery that could lead to more effective treatments for people living with multiple sclerosis (MS). The study found that drugs targeting the IL-17 molecule may not need to get across the blood-brain-barrier to be effective in treating MS.
A new drug called Myeliviz has been approved for its first human trials to aid multiple sclerosis (MS) diagnoses. The drug targets and binds to myelin, allowing for its imaging by a PET scanner, potentially providing earlier and more accurate diagnoses.
A new technique reveals that myelin produces multiple waves of electrical potentials traveling at high speeds, contradicting earlier assumptions. This discovery has significant implications for understanding demyelinating diseases like multiple sclerosis.
A study published in Environmental Health found a link between air pollution from traffic and an increased risk of developing dementia, Parkinson's disease, Alzheimer's disease, and multiple sclerosis. Living near green spaces appears to have protective effects against these neurological disorders.
Researchers at UMass Chan Medical School have developed a gene therapy approach that protects synaptic connections in the brain from damage in multiple sclerosis models. The study suggests that therapies targeting specific circuits of the brain could be effective in preserving vision and preventing neurodegenerative symptoms.
Researchers at Kessler Foundation identified specific brain regions associated with memory rehabilitation using the modified Story Memory Technique. Participants showed decreased brain activity in language network, default mode network, and executive control network, leading to improved learning and memory outcomes.
The cost of MS drugs increased from $453 million to $1.32 billion between 2011 and 2017, driven by prescription costs that doubled during this period.
Researchers identify Protease Activated Receptor 1 (PAR1) as a molecular switch that promotes myelin regeneration, potentially improving function in neurological disorders. The study's findings suggest new strategies for treating diseases of the central nervous system.
A clinical trial is testing an experimental stem cell treatment against the best available biologic therapies for severe forms of relapsing multiple sclerosis. The trial aims to determine whether autologous hematopoietic stem cell transplantation (AHSCT) is an effective and durable treatment option for people with severe relapsing MS w...
Researchers identified deficits in prospective memory as factors affecting performance of everyday life activities in individuals with multiple sclerosis. Time-based tasks showed poorer performance compared to event-based tasks, and were associated with executive function deficits and lower motor scores.
A working group of medical organizations analyzed 29 pivotal phase III trials for disease-modifying drugs in MS, finding that patient symptoms and quality of life were often not considered. They suggest improving studies by focusing on patient-reported outcomes and long-term treatment effects.
A study found that individuals with multiple sclerosis who struggle with money management have difficulty with executive functioning and low depressive symptomatology. This can lead to serious financial, legal, and psychological consequences. Understanding these underlying factors is crucial for identifying those at risk and providing ...
A new study by University of Wisconsin-Madison researchers found that changes in VEP latency can accurately reflect remyelination in multiple sclerosis patients, providing a potential outcome measure for evaluating new treatments.
Researchers conducted a literature review to summarize outcomes in patients with MS who smoke cigarettes and are exposed to smoke. The study found associations between cigarette smoking and increased risk of MS relapses, disability, and mortality.
Research finds gut protein Smad7 mobilizes immune cells, triggering inflammation in the central nervous system of MS patients. Analyzing intestinal tissue samples from MS patients confirms results, suggesting a potential therapeutic target for this debilitating disease.
A team of investigators from Brigham and Women's Hospital has identified a specific microRNA, miR-30d, that increases during peak disease in MS patients. Orally administering a synthetic version of the microRNA prevented disease in a preclinical mouse model.
Researchers at Karolinska Institutet developed a new method to separate between two types of herpes virus 6A and 6B, found that MS-patients carry the virus 6A to a greater extent than healthy individuals, and that HHV-6A may be contributing factor to multiple sclerosis development
A study found that MS drug prices are increasing due to profit-driven business models, with executives citing the US market as a key factor. The researchers noted that prices in the US continue to rise despite decreased production costs.
Researchers found associations between sensory difficulties, cognitive impairments, and disease severity in individuals with multiple sclerosis. Sensory processing deficits also affected functional performance of everyday life activities.
A study published in Science Translational Medicine founds that blocking the molecule ALCAM can delay the progression of multiple sclerosis. The disease causes symptoms such as fatigue, lack of coordination and vision problems in people like 20,000 Canadians with the disease.
Researchers used powerful imaging technology to discover a common indicator of brain inflammation in early-stage MS patients and its link to gray matter damage. The study found LME was present in nearly two-thirds of the patients, with significant correlations to lesions in gray matter regions.
A recent study published in Neurology reveals that individuals with multiple sclerosis (MS) who also suffer from depression are more likely to experience debilitating symptoms earlier than those without depression. The research highlights the need for early recognition and treatment of depressive symptoms in patients with MS.
The Center for BrainHealth has awarded five scientists with innovative research grants to study brain health and performance. These studies aim to improve understanding of brain disorders and develop new treatments, including biomarkers for dementia and multiple sclerosis.
A study at Johns Hopkins Medicine identified three complement system genes linked to MS-caused vision loss. The researchers found that patients with specific genetic changes in these genes were more likely to experience severe vision problems, opening up new avenues for precision medicine and potential treatments.
Researchers at TalTech have identified a new receptor, P2X4, in human eosinophils that plays a key role in the communication between the immune system and nervous system. The discovery has implications for understanding multiple sclerosis and cancerous lesions.
A recent study found that risk factors for unemployment among individuals with multiple sclerosis (MS) differ by age group. Factors such as physical symptoms, psychological issues, and person-specific traits were identified as contributing to the high unemployment rate among MS patients, with younger and older adults experiencing diffe...
Dr. Bruce Alberts will receive the 2020 John Edward Porter Legacy Award for his commitment to scientific research and education. The award recognizes his efforts to promote science as inquiry and improve science education in primary and secondary schools.
Researchers at UVA School of Medicine found that oligodendrocyte progenitor cells, previously thought to be harmless, actively participate in the immune system's attacks on myelin in multiple sclerosis. This discovery offers new hope for finding a cure by promoting brain repair and targeting both aspects of the pathology.
A new grant from the Consortium of Multiple Sclerosis Centers will allow researchers to investigate different types of exercise regimens in individuals with multiple sclerosis. The study aims to measure the effects of exercise on various aspects of MS-related symptoms, such as cognition, fatigue, and physical functioning.
Researchers identified a specific subgroup of helper T cells driving MS and found that targeting the CXCR6 protein prevented and reversed the disease in mouse models. Elevated levels of CXCR6-positive cells were also found in inflamed joints of patients with inflammatory autoimmune arthritis.
A new study has identified 233 genetic sites that contribute to multiple sclerosis (MS) susceptibility, highlighting the involvement of peripheral immune cells and microglia. The findings confirm earlier results and provide a rich perspective on the molecular events leading to MS.
Researchers found that neuropsychological tests have predictive value for everyday life activities in individuals with MS. However, non-cognitive variables and person-specific factors also play a crucial role in evaluating the impact of the disease on daily functioning.
A new tablet-based app offers a faster, easier, and more accurate way to assess the cognitive function of people with multiple sclerosis. The app, called iCAMS, reduced test time from about 23 minutes to 14 minutes while producing highly accurate results.
Researchers at Oregon Health & Science University have developed a compound that successfully promotes rebuilding of damaged nerve cell protective sheath, reversing MS symptoms. The discovery may lead to clinical trials in humans with MS or other neurodegenerative conditions.
A recent study by Kessler Foundation researchers linked deficits in social cognition with symptoms of fatigue, depressive symptomatology, and anxiety in individuals with multiple sclerosis. The study highlights the interplay between social cognition, mood, and fatigue in MS patients.
The American Academy of Neurology has issued a new guideline recommending that people with multiple sclerosis receive recommended vaccinations, including yearly flu shots. The guideline updates previous recommendations and emphasizes the importance of preventing infections through vaccine use in MS patients.
A recent study found that Medicare patients with multiple sclerosis have seen a significant increase in out-of-pocket costs for their medications over the past decade. The cost of these drugs has risen more than sevenfold, affecting not only the patients but also the healthcare system as a whole.
Researchers identify various disease mechanisms underlying progressive MS, highlighting the need for precise therapy approaches targeting different pathomechanisms. Financial obstacles, including patent expirations, also hinder the development of new drugs.
A University at Buffalo-led study found that a vegetable-rich diet can improve fatigue in multiple sclerosis patients by increasing good cholesterol levels. The results suggest that lipid metabolism plays a crucial role in fatigue and may provide new treatment options for this debilitating symptom.
A recent NIH study found that chronic active lesions in the brain, marked by dark rimmed spots, are a hallmark of more aggressive and disabling forms of multiple sclerosis. The study suggests that these lesions may play a role in progressive MS and offers hope for developing new treatments.
A new Stanford study found that stimulating a protective immune cell class, CD8 T cells, may reduce autoimmune disease severity. In a mouse model of multiple sclerosis, injecting mice with peptides recognized by these cells reduced disease severity and killed disease-causing immune cells.
A large-scale analysis of over 200,000 individuals found no positive correlation between vaccinations and the development of multiple sclerosis. MS patients were statistically less likely to receive vaccinations before diagnosis than comparator groups.
A $1,825,742 NIH grant will fund a randomized controlled trial of strategy-based cognitive training in individuals with multiple sclerosis. The study aims to develop a treatment that improves everyday functioning and neuropsychological performance in those affected by the condition.
Researchers at the Center for BrainHealth have developed a novel diagnostic method for multiple sclerosis that uses 3D images of brain lesions to determine healing capacity. The technology has the potential to help doctors tailor treatment plans and improve patient outcomes.
PCORI is funding two projects to expand use of PCORI-funded research findings in real-world practice. A $1.4 million project aims to increase lung cancer screening rates, while an $860,000 project seeks to improve care for adolescents with TBI through a self-guided online therapy program.
Researchers have discovered that projection neurons are damaged by immune cells in MS patients' brains, leading to brain shrinkage and cognitive changes. This finding provides a platform for targeted therapies to be developed.
Researchers have identified ceramides, a type of lipid, as key contributors to neuronal damage in progressive multiple sclerosis (MS) patients. The study found that exposure to cerebrospinal fluid from progressive MS patients caused mitochondrial dysfunction and increased energy demand, leading to neuronal demise.
A single-center study of 453 children with multiple sclerosis found a significant association between obesity and increased risk of pediatric MS. The study also explored the response of first-line therapy in obese children with MS, but no conclusive findings were reported.
Researchers suggest that viruses hiding in our DNA could be causing some of our deadliest neurological diseases. Studies link HERV reactivation to autoimmune attacks in multiple sclerosis and peripheral demyelinating disease CIDP.
A new study has shown that people with progressive multiple sclerosis (MS) experience significant improvements in movement and balance thanks to a specialized standing frame. The intervention also appeared cost-effective, leading researchers to conclude it could be routinely implemented within MS care throughout the UK.
A comprehensive study of MS patients found that gadolinium deposition occurs early in the disease, but does not have a clinical impact. However, male patients showed more deposition than female patients, which may be related to dosage based on weight.
A novel PET tracer has been used to detect abnormal inflammation in the grey matter of patients with progressive multiple sclerosis, linked to physical disability and brain atrophy. The study provides a new tool for assessing disease progression and predicting treatment effects.
A 65-year follow-up study of nearly 7,000 Norwegian patients with multiple sclerosis found an overall risk of developing cancer 14% higher than the general population. Respiratory cancer risk was particularly high at 66%, while urinary and central nervous system cancer risks were also significantly increased.
A new study published in PNAS reveals that the HERV-W envelope protein drives CNS microglial cells to damage myelinated axons in MS patients. Clinical trials have shown promising results with temelimab, an ENV-neutralising antibody that blocks the retrovirus's activity.
A recent study by Kessler Foundation researchers found evidence for differential effects of progressive MS on cognitive and affective Theory of Mind. The study used Virtual Assessment of Mentalising Ability (VAMA) to measure Theory of Mind in individuals with progressive MS, who showed poorer performance on the cognitive ToM subtest co...
Researchers Drs. Shenoy Handiru and Katie Lancaster at Kessler Foundation will investigate novel ways to improve rehabilitative care for disabilities caused by stroke and multiple sclerosis. The projects aim to enhance hand function in stroke patients and alleviate feelings of stress and anxiety in individuals with MS.
A study of 5,704 patients with MS found that those with pediatric-onset disease had lower test scores and faster declining cognitive abilities. Patients with pediatric-onset MS were also more likely to experience cognitive impairment compared to those with adult-onset MS.
Researchers discovered 12 genes that increase MS risk in families with multiple members affected by the disease. They found a common biological process leading to increased inflammation, paving the way for personalized treatments and preventative strategies.
A new nanotechnology treatment using exosomes extracted from bone marrow stem cells has reversed MS symptoms in mice by rejuvenating lost motor skills and decreasing nerve damage. The treatment will be tested on humans in early 2020, initially on people with Type 1 diabetes.